Zacks Investment Research cut shares of Corindus Vascular Robotics (NYSEAMERICAN:CVRS) from a hold rating to a sell rating in a research note released on Monday, January 29th.
According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “
Other analysts have also recently issued reports about the company. BidaskClub cut Corindus Vascular Robotics from a sell rating to a strong sell rating in a report on Wednesday, October 11th. ValuEngine cut Corindus Vascular Robotics from a hold rating to a sell rating in a report on Tuesday, October 3rd. Three research analysts have rated the stock with a sell rating and two have issued a buy rating to the company. Corindus Vascular Robotics has an average rating of Hold and an average target price of $2.33.
Shares of Corindus Vascular Robotics (CVRS) opened at $0.90 on Monday. Corindus Vascular Robotics has a 1 year low of $0.52 and a 1 year high of $2.25. The firm has a market capitalization of $177.48, a P/E ratio of -3.75 and a beta of 19.34.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its position in Corindus Vascular Robotics by 40.7% during the second quarter. Bank of New York Mellon Corp now owns 229,380 shares of the medical equipment provider’s stock worth $426,000 after buying an additional 66,368 shares in the last quarter. Essex Investment Management Co. LLC purchased a new position in Corindus Vascular Robotics during the third quarter worth $1,213,000. Schwab Charles Investment Management Inc. increased its position in Corindus Vascular Robotics by 34.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 383,800 shares of the medical equipment provider’s stock worth $584,000 after buying an additional 97,900 shares in the last quarter. Teachers Advisors LLC increased its position in Corindus Vascular Robotics by 184.7% during the second quarter. Teachers Advisors LLC now owns 167,633 shares of the medical equipment provider’s stock worth $312,000 after buying an additional 108,745 shares in the last quarter. Finally, Northern Trust Corp increased its position in Corindus Vascular Robotics by 42.4% during the second quarter. Northern Trust Corp now owns 959,920 shares of the medical equipment provider’s stock worth $1,786,000 after buying an additional 285,811 shares in the last quarter.
ILLEGAL ACTIVITY WARNING: “Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Downgraded by Zacks Investment Research” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/15/zacks-investment-research-downgrades-corindus-vascular-robotics-cvrs-to-sell.html.
Corindus Vascular Robotics Company Profile
Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.
Get a free copy of the Zacks research report on Corindus Vascular Robotics (CVRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.